ZYMEZymeworks Inc.vs its industry peers
A metric-by-metric comparison of Zymeworks Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYMEThis | $1.6B#8 | — | 9.7x#12 | 15.0x#9 | 38.9%#6 | 33.9%#5 | -87.3%#7 | -49.6%#12 | — | — | 73.8%#8 | — |
| ABCL | $1.8B#2 | — | 1.9x#4 | 23.7x#10 | 160.6%#3 | 10.1%#8 | -289.0%#11 | -15.6%#5 | -25.2%#5 | — | 37.4%#11 | — |
| TYRA | $1.9B#1 | — | 4.9x#10 | — | — | -38.7%#9 | — | -30.9%#9 | — | — | 209.7%#2 | — |
| DMRA | $1.8B#3 | 5.4x#2 | 3.4x#7 | — | — | -878.8%#14 | — | -41.0%#10 | — | — | 815.4%#1 | — |
| SNDX | $1.7B#4 | — | 40.9x#13 | 9.9x#7 | 627.8%#2 | 10.5%#7 | -158.4%#10 | -685.7%#16 | -107.2%#8 | — | 92.8%#7 | — |
| BCAX | $1.7B#5 | — | 3.3x#6 | — | — | -102.9%#10 | — | -26.8%#8 | — | — | 144.6%#4 | — |
| SRPT | $1.7B#6 | 45.4x#3 | 1.1x#2 | 0.9x#2 | 4.3%#10 | -403.3%#12 | -37.5%#6 | -47.4%#11 | -67.2%#7 | — | -0.1%#14 | — |
| TRAX | $1.6B#7 | — | 6.3x#11 | — | — | — | — | 0.0%#2 | — | — | — | — |
| SEPN | $1.6B#9 | — | 4.2x#8 | 34.2x#11 | 4174.5%#1 | 31.9%#6 | -148.6%#9 | -12.9%#4 | — | — | 185.7%#3 | — |
| ANAB | $1.6B#10 | — | 122.4x#16 | 6.7x#6 | 157.0%#4 | 90.9%#2 | 20.4%#2 | -103.8%#15 | — | — | 117.2%#6 | — |
| INVA | $1.5B#11 | 3.3x#1 | 1.1x#3 | 3.7x#3 | 14.7%#8 | — | 39.8%#1 | 0.0%#2 | 13.6%#2 | — | 11.5%#13 | — |
| PRGO | $1.5B#12 | — | 0.6x#1 | 0.3x#1 | -2.8%#11 | -729.7%#13 | -26.4%#5 | -57.0%#14 | -19.7%#4 | 4#2 | -55.6%#15 | 10.8%#1 |
| HROW | $1.5B#13 | — | 50.7x#14 | 5.3x#5 | 36.4%#7 | 70.6%#3 | 11.2%#3 | -17.9%#7 | 13.0%#3 | 5#1 | 25.2%#12 | — |
| XNCR | $1.4B#14 | — | 2.8x#5 | 11.5x#8 | 13.7%#9 | 60.5%#4 | -141.4%#8 | -17.8%#6 | -29.1%#6 | — | 143.9%#5 | — |
| XERS | $1.4B#15 | 116.1x#4 | 107.8x#15 | 4.8x#4 | 43.7%#5 | 101.0%#1 | 8.5%#4 | 4.3%#1 | 20.3%#1 | — | 51.3%#10 | — |
| AVBP | $1.4B#16 | — | 4.3x#9 | — | — | -106.6%#11 | — | -51.3%#13 | — | — | 59.2%#9 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-08-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice